Everolimus, an mTOR inhibitor, is approved in combination with exemestane for advanced breast cancer with endocrine resistance, having demonstrated improved PFS versus exemestane alone in the BOLERO-2 trial [6, 7]; however, in contrast to some CDK4/6 inhibitors [3, 4], OS benefit was not observed. This evidence concerns the gene MTOR and breast cancer.